A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21.


We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Adoptive Transfer
  • Female
  • Humans
  • Ovarian Neoplasms* / therapy
  • T-Lymphocytes
  • Vaccination
  • Vaccines*


  • Vaccines